LACIVITA, ENZA
 Distribuzione geografica
Continente #
NA - Nord America 5.422
EU - Europa 1.057
AS - Asia 569
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 7.055
Nazione #
US - Stati Uniti d'America 5.417
CN - Cina 389
SE - Svezia 359
DE - Germania 161
IT - Italia 140
UA - Ucraina 118
SG - Singapore 111
GB - Regno Unito 99
FI - Finlandia 92
VN - Vietnam 25
IN - India 24
FR - Francia 22
IE - Irlanda 21
BE - Belgio 19
RU - Federazione Russa 14
HK - Hong Kong 7
IR - Iran 5
JP - Giappone 5
AU - Australia 4
CA - Canada 3
RO - Romania 3
DM - Dominica 2
EU - Europa 2
NL - Olanda 2
PL - Polonia 2
TR - Turchia 2
AT - Austria 1
BG - Bulgaria 1
CL - Cile 1
CZ - Repubblica Ceca 1
GR - Grecia 1
KZ - Kazakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 7.055
Città #
Fairfield 874
Woodbridge 565
Chandler 406
Houston 393
Ashburn 373
Seattle 369
Cambridge 314
Ann Arbor 312
Wilmington 292
Jacksonville 279
Nyköping 276
Roxbury 114
Lawrence 110
Nanjing 97
Bari 94
Singapore 88
Beijing 83
Boardman 80
New York 80
Princeton 68
Des Moines 64
Inglewood 55
San Diego 39
Brooklyn 32
Shenyang 27
Dong Ket 25
Jiaxing 22
Dublin 21
Nanchang 21
Hebei 20
Pune 20
London 19
Santa Clara 19
Brussels 17
Paris 17
Unterföhring 17
Changsha 16
Los Angeles 14
Norwalk 14
Tianjin 13
Dearborn 11
Falls Church 11
Frankfurt am Main 10
Indiana 8
Shanghai 8
Guangzhou 7
Helsinki 7
Redwood City 7
Hong Kong 6
Taizhou 5
Wuxi 5
Acquaviva delle Fonti 4
Chiswick 4
Naples 4
Ardabil 3
Ercolano 3
Kansas City 3
Leawood 3
New Bedfont 3
Rome 3
San Francisco 3
Tappahannock 3
Washington 3
Wuhan 3
Acton 2
Augusta 2
Bitonto 2
Boydton 2
Bąków 2
Clifton 2
Dalian 2
Ferrara 2
Fuzhou 2
Hangzhou 2
Hanover 2
Hefei 2
Islington 2
Istanbul 2
Jinan 2
Jinhua 2
Munich 2
Ningbo 2
Patna 2
Qingdao 2
Roseau 2
Toronto 2
Waanrode 2
West Jordan 2
Adelfia 1
Almaty 1
Auburn Hills 1
Bratislava 1
Brisbane 1
Brno 1
Bucharest 1
Castellammare Di Stabia 1
Central 1
Centrale 1
Chizhou 1
Dongyang 1
Totale 5.946
Nome #
Long-lasting beneficial effects of central serotonin receptor 7 stimulation in female mice modeling Rett syndrome. 134
Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics. 134
Persistent modification of forebrain networks and metabolism in rats following adolescent exposure to a 5-HT7 receptor agonist 133
Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X Syndrome 128
5-HT7 receptor activation: procognitive and antiamnesic effects 115
ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. 113
Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2 112
Novel Derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Improved Fluorescent and σ Receptors Binding Properties 107
Activation of 5-HT7 receptor by administration of its selective agonist, LP-211, modifies explorative-curiosity behavior in rats in two paradigms which differ in visuospatial parameters 107
Analogues of σ Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Added Polar Functionality and Reduced Lipophilicity for Potential Use as Positron Emission Tomography Radiotracers 106
Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2. 105
Activation of Serotonin 5-HT7 Receptors Modulates Hippocampal Synaptic Plasticity by Stimulation of Adenylate Cyclases and Rescues Learning and Behavior in a Mouse Model of Fragile X Syndrome 100
Structure-Activity Relationships and Therapeutic Potentials of 5-HT7 Receptor Ligands: An Update 99
Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [18F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide. 99
Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder 99
The 5-HT7 receptor triggers cerebellar long-term synaptic depression via PKC-MAPK 99
5 HT1A receptor, an old target for new therapeutic agents 97
Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress 97
Stimulation of the brain serotonin receptor 7 rescues mitochondrial dysfunction in female mice from two models of Rett syndrome 96
3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: Molecular modeling of chiral recognition by FPR2. 94
POLYCYCLIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF 94
The brain-penetrant 5-HT7receptor agonist LP-211 reduces the sensory and affective components of neuropathic pain 94
Interplay between Serotonin 5-HT1A and 5-HT7 Receptors in Depressive Disorders. 92
Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions 92
Synthesis, radiolabeling and in vivo evaluation of [11C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT7 receptor 89
Structural Determinants in the Binding of BB2 Receptor Ligands: In Silico, X-Ray and NMR Studies in PD176252 Analogues. 88
Bivalent ligand approach on 4-[2-(3-methoxyphenyl)ethyl]-1-(2-methoxyphenyl)piperazine: Synthesis and binding affinities for 5-HT7 and 5-HT1A receptors 85
LP-211, a selective 5-HT7receptor agonist, increases novelty-preference and promotes risk-prone behavior in rats 85
5-HT7 receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009) 84
Activatable fluorescent probes: a new concept in optical molecular imaging 83
Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT₇ receptor. 83
The therapeutic potential of 5-HT1A receptors: a patent review. 82
Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders 81
The arylpiperazine derivatives N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide and N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide exert a long-lasting inhibition of human serotonin 5-HT7 receptor binding and cAMP signaling. 81
Selective agonists for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview. 81
LP-211 is a brain penetrant selective agonist for the serotonin 5-HT7 receptor 80
The microRNA-29a Modulates Serotonin 5-HT7 Receptor Expression and Its Effects on Hippocampal Neuronal Morphology 79
Modulatory effects of two novel agonists for serotonin receptor 7 on emotion, motivation and circadian rhythm profiles in mice 78
Differential responses to acute administration of a new 5-HT7-R agonist as a function of adolescent pre-treatment: phMRI and immuno-histochemical study. 77
Investigations on the 1-(2-biphenyl)piperazine motif. Identification of new potent and selective ligands for the serotonin7 (5-HT7) receptor with agonist or antagonist action in vitro or ex vivo. 77
Structural insights into serotonin receptor ligands polypharmacology 76
Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters 76
Stimulation of 5-HT7 receptor during adolescence determines its persistent upregulation in adult rat forebrain areas 76
N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands 75
Serotonin 5-HT7 receptor increases the density of dendritic spines and facilitates synaptogenesis in forebrain neurons 75
Synthesis and Biological Evaluation of Potential Positron Emission Tomography (PET) Ligands for Brain Visualization of Dopamine D3 Receptors. 73
Determination of 1-aryl-4propylpiperazine pKa values: the substituent on aryl modulates basicity 73
Selective 5-HT7 receptor agonists LP 44 and LP 211 elicit an analgesic effect on formalin-induced orofacial pain in mice 71
Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation 71
Aurantiamide-related dipeptide derivatives are formyl peptide receptor 1 antagonists 69
The medicinal chemistry of 5-HT2C receptor ligands 68
null 68
Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome 66
Developments in fluorescent probes for receptor research 66
Structural modifications of the serotonin 5-HT7 receptor agonist N -(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve in vitro microsomal stability: A case study 66
Novel 64Cu Labeled RGD2-BBN Heterotrimers for PET Imaging of Prostate Cancer 66
Synthesis and biological evaluation of potential positron emission tomography (PET) ligands for brain visualization of dopamine D3 receptors 65
Increase of Capsaicin-Induced Trigeminal Fos-Like Immunoreactivity by 5-HT(7) Receptors. 65
Emotional and risk seeking behavior after prepuberal subchronic or adult acute stimulation of 5-HT7-Rs in naples high excitability rats. 65
11C-Labeling of N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide derivatives and evaluation as potential radioligands for PET imaging of dopamine D3 receptors 65
Potentiation of capsaicin-induced neurogenic inflammation by 5-HT7 receptors in the rat hind paw: Involvement of calcitonin gen-related peptide 64
New 1-arylpiperazinic ligands of 5-HT7 receptor and use thereof 62
Identification of a red-emitting fluorescent ligand suitable for in vitro 5-HT1A receptor visualization 57
Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors 57
Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II 56
BEHAVIOURAL EFFECTS OF TWO NOVEL AGONISTS FOR SEROTONIN RECEPTOR 7 IN MICE 55
trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT1A receptor ligands as conformationally constrained analogs of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines 53
Prior Activation of 5-HT7 Receptors Modulates the Conditioned Place Preference With Methylphenidate 53
N-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 ligands 51
N-[omega-[4-(2-Methoxyphenyl)-1-piperazinyl]alkyl]-2-quinolinamines as High-Affinity Fluorescent 5-HT1A Receptor Ligands 49
Radiosynthesis and in vivo Evaluation of Carbon-11 (2S)-3-(1H-Indol-3-yl)-2-[(4-methoxyphenyl)carbamoyl]amino-N-[1-(5-methoxypyridin-2-yl)cyclohexyl]methylpropanamide: An Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of Neuroinflammation 49
Selective Agents for Serotonin2C (5-HT2C) Receptor 49
Development of a PET radioligand for the 5-HT7 receptor. Preliminary characterization using autoradiography 48
Design and synthesis of arylpiperazine-based fluorescent ligands for serotonin 5-HT1A and dopamine D3 receptors. 48
Prepuberal Stimulation of 5-HT7-R by LP-211 in a Rat Model of Hyper-Activity and Attention-Deficit: Permanent Effects on Attention, Brain Amino Acids and Synaptic Markers in the Fronto-Striatal Interface. 47
PREVENTION AND TREATMENT OF RETT SYNDROME 45
Pharmacological Stimulation of the Brain Serotonin Receptor 7 as a Novel Therapeutic Approach for Rett Syndrome. 45
First structure–activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure 44
4-[omega-[4-arylpiperazin-1-yl]phenyl)imidazo[1,2-a]pyridine derivatives: fluorescent high-affinity dopamine D3 receptor ligands as potential probes for receptor visualization 44
Design synthesis, and binding affinity of potential positron emission tomography (PET) ligands for visualitation of brain dopamine D3 receptors 43
The GR-127935-sensitive mechanism mediating hypotension in anesthetized rats: are 5-HT5B receptors involved? 43
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function 43
Design, synthesis, radiolabeling and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential Positron Emission Tomography tracer for the dopamine D4 receptors 42
Design, synthesis, radiolabeling and in vivo biological evaluation of potential 5-Ht7 receptor PET tracers: Structural modifications of the selective agonist Lp-211 41
N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides as 5-HT7 receptor agents 41
null 40
Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 receptor ligands 38
Recent advances in the field of 5-HT7 receptor agents with 1-arylpiperazine structure. 36
N-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 ligands 36
Modulatory effects following subchronic stimulation of brain 5-HT7-R system in mice and rats. 35
Fluorescent probes: from bench to bedside 34
Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter(SERT)and 5-HT1A receptors 33
THE ARYLPIPERAZINE DERIVATIVES LP-211 AND MEL-9 ARE INACTIVATING ANTAGONISTS AT HUMAN SEROTONIN 5-HT7 RECEPTORS 32
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2 30
G-protein coupled receptors involved in the resolution of inflammation: Ligands and therapeutic perspectives 29
Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III 29
Privileged scaffold-based design to identify a novel drug-like 5-HT7 receptor-preferring agonist to target Fragile X syndrome 29
The contribution of formyl peptide receptor dysfunction to the course of neuroinflammation: A potential role in the brain pathology 28
The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Improves Ex Vivo and In Vivo Amyloid Beta (1–42)-Induced Neuroinflammation in Mouse Models of Alzheimer’s Disease 27
Selective serotonergic 5-HT7 receptor agonists as a new therapeutic venue for treatment of cognitive disorders: focus on Fragile X syndrome. 27
Totale 6.966
Categoria #
all - tutte 32.791
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.791


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.529 0 0 0 181 222 122 180 184 235 154 146 105
2020/20211.104 88 93 63 74 102 53 135 91 79 161 81 84
2021/2022900 51 115 29 34 41 67 46 49 84 47 150 187
2022/20231.209 213 105 83 91 162 156 17 141 187 4 26 24
2023/2024452 30 82 27 15 34 114 13 15 26 17 19 60
2024/2025279 69 11 189 10 0 0 0 0 0 0 0 0
Totale 7.337